BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230908
DTSTAMP:20260516T004834
CREATED:20230519T095236Z
LAST-MODIFIED:20230519T095236Z
UID:37210-1693872000-1694131199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Immunogenicity Summit 2023
DESCRIPTION:The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with likeminded peers from gene therapy drug developers\, along with leading academics\, regulators\, and key service providers\, all making strides with improving risk assessments\, monitoring\, and mitigating against AAV gene therapy immunogenicity. \nRegistering for 2023 will grant you access to keynote plenaries from leading gene therapy figures\, deep-dive discussions into pressing preclinical and clinical developments\, and highly appraised networking opportunities with 150+ of your peers\, all to leave you with the actionable tools\, insights\, and connections you need to enhance your immunogenicity-focused work. \nTo know more visit: https://ter.li/vk8xwq
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-immunogenicity-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230909
DTSTAMP:20260516T004834
CREATED:20230606T104920Z
LAST-MODIFIED:20230606T104920Z
UID:37280-1693872000-1694217599@www.pharmajournalist.com
SUMMARY:13th World Clinical Biomarkers & CDx Boston 2023
DESCRIPTION:The hotly anticipated 13th World Clinical Biomarkers & CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization\, reimbursement and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster. \nWhether you are working in Oncology\, NASH\, or Neuroscience\, join 600+ Directors\, Heads and VPs of Clinical Biomarkers\, Translational Medicine\, Precision Medicine & Companion Diagnostics together with drug and diagnostic developers\, regulatory experts\, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes. \nTo know more visit: https://ter.li/849j6q
URL:https://www.pharmajournalist.com/event/13th-world-clinical-biomarkers-cdx-boston-2023/
LOCATION:Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230911
DTEND;VALUE=DATE:20230914
DTSTAMP:20260516T004834
CREATED:20230704T143300Z
LAST-MODIFIED:20230704T143518Z
UID:37419-1694390400-1694649599@www.pharmajournalist.com
SUMMARY:7th Complement-Based Drug Development Summit
DESCRIPTION:With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023\, the Complement-Based Drug Development Summit is returning for its 7th year in a timely fashion. Be the first to view this year’s Event Guide below! \n7th Complement-Based Drug Development Summit\nSeptember 11-13\, 2023\nView Agenda \nReuniting experts across Nephrology\, Neurology\, Ophthalmology\, and Haematology\, join the leading companies showcasing the latest preclinical and clinical progress for complement-based therapeutics. \n\nWith 30+ expert speakers from: AGTC\, Alexion\, Alnylam\, Amgen\, Annexon\, Apellis – and that’s just the A’s!\nCovering more complement targets than ever before including C5aR2\, Factor Bb and Combination Therapy\, alongside an increased coverage of diseases\nFull of content for your whole team covering the most pressing challenges – from evaluating the value proposition of different fragments to target to designing clinical trials with high-risk patient populations\n\n \n​​​​View the full list of sessions and expert speakers here. \n​​​​​​This world-class speaker faculty will evaluate the entirety of the complement landscape\, from scientific understanding to strategic\, commercial intelligence. This means that no matter your role in the field\, you’ll leave with tangible insights to further develop your complement pipeline.
URL:https://www.pharmajournalist.com/event/7th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260516T004834
CREATED:20230714T121304Z
LAST-MODIFIED:20230714T121304Z
UID:37455-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:LNP Characterization & Analytical Development Summit
DESCRIPTION:Fingerprinting Your LNP Drug Product Quality\, Safety\, Efficacy & Regulatory Compliance \nWith the recent breakthroughs from Verve Therapeutics\, Vertex-Arbor Bio\, and Mana.bio propelling the field of LNP technology forward at lightning speed beyond mRNA vaccines\, the LNP Characterization & Analytical Development Summit is your must-attend meeting to deep dive into the latest technologies and approaches throughout product lifecycle and strengthen your lipid nanoparticle characterization\, bioanalytical and assay development competencies. \nWith unmissable case studies from the likes of Pfizer\, Moderna\, AstraZeneca\, Ultranegyx\, Merck and SINTEF\, this is the definitive forum to benchmark and learn with the LNP community who unite for the first time. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nAnalyze LNP structure and morphology to relay into functional data and analytical practices with Ultragenyx and Pfizer\nOptimize the characterization of payloads to foresee the outcome of the LNP complex with Hopewell Therapeutics\, Beam Therapeutics and Moderna\nDevelop assays which align with mechanisms of action and portray total functionality of the LNP with NIST\, Editas Medicine and AstraZeneca\n\nDon’t miss this opportunity to supercharge your analytics\, and together with 60+ characterization and analytical scientists\, get inspiration to derive best practice\, and support next generation of therapeutics to patients with safety and efficacy. \nTo know more visit: https://ter.li/z7dmih
URL:https://www.pharmajournalist.com/event/lnp-characterization-analytical-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260516T004834
CREATED:20230720T121753Z
LAST-MODIFIED:20230720T121753Z
UID:37490-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:3rd Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:Your one-stop shop to capturing industry’s most exciting developments to tackle rare & genetic kidney diseases. From evaluating real-world outcomes to uncovering underlying pathophysiology to interrogating translational models\, the 3rd Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to give industry the opportunity to unite towards a shared goal and share strategic insights to move from bench to bedside and bring efficacious therapies to patients faster. \nTo know more visit: https://ter.li/jy2ot0
URL:https://www.pharmajournalist.com/event/3rd-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230913
DTEND;VALUE=DATE:20230915
DTSTAMP:20260516T004834
CREATED:20230810T114925Z
LAST-MODIFIED:20230810T114925Z
UID:37605-1694563200-1694735999@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices USA
DESCRIPTION:Wearable Injectors and Connected Devices USA  \nConference: September\, 13 – 14 2023  \nBoston\, USA  \nWebsite: http://www.wearableinjectors-usa.com/PharmaJournalist-EL \nAdvancing digital health and on-body drug delivery devices for enhanced patient experience  \nFollowing the success of the Wearable Injectors and Connected Devices Europe conference\, SAE Media Group will be bringing the conference to Boston to cater to Big Pharma\, Biotech and Device Developers in the USA. \nAs the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. The conference will delve into on-body device design and development\, latest advances in connectivity and digital integration of wearable devices\, and opportunities for enhancement of user-interface through human factors case studies. The conference will also address challenges in regulations surrounding wearable injectors and connected devices with case studies and an FDA keynote on cybersecurity. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in September 2023! \nKey Reasons to Attend: \n\nDiscover the latest advances in wearable injector design and development as well as emerging technologies for improved drug delivery\nUnderstand and gain insight into the regulations surrounding electronic devices and wearable injectors such as labelling requirements and clinical study expectations\nDelve into the digital integration of medical devices for improved user experience and strategies to ensure connected ecosystems are safe with an FDA Cybersecurity update\nBenchmark against connected injector case studies and gain insight into key considerations during development such as battery selection\nEngage in the latest strategies for implementing user centricity into device design to meet patient needs and increase adherence\n\nWHO SHOULD ATTEND? \nDevice Developers \nCombination Product Developers \nSmart Packaging Developers and Designers \nSmart Device Developers \nDrug- Delivery Developers \nConnected/Digital Health Developers
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-usa/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230922
DTSTAMP:20260516T004834
CREATED:20230726T074357Z
LAST-MODIFIED:20230726T074357Z
UID:37521-1695081600-1695340799@www.pharmajournalist.com
SUMMARY:7th IPF Summit
DESCRIPTION:FIbroGen’s recent Phase 3 trial failure for pamrevlumab exemplifies the critical time point the pulmonary fibrosis field is currently at as drug developers move through in-human to Phase 2 to Phase 3 trials to get the next disease-modifying drug to the patients in need. \nThe 7th IPF Summit (September 19-21 | Boston) returns at this crucial stage for the drug development and academic communities to come together to address R&D bottlenecks\, troubleshoot key discovery challenges\, and share exclusive data to accelerate the latest ideas and innovations in the IPF field and supercharge a new era of IPF therapeutics. \nIf you haven’t yet seen the line-up of 42+ expert speakers\, take a look at the full program in the event guide! \nAre you looking to address and solve challenges with IPF therapeutic development\, such as:   \n\nUnderstanding cell cross-talk in the lung pathobiology of IPF\, including epithelial and endothelial cells\nHarnessing precision medicine for IPF including patient selectivity\, combinational therapies\, and biomarkers\nWhether to incorporate imaging into your preclinical and clinical development and the potential of using imaging as an endpoint in IPF?\n\nThen this is the event for you! This is your unique opportunity to leverage knowledge from world-leading IPF industry experts and KOL academics on the latest developments to overcome\, discovery\, preclinical\, translational\, and clinical\, challenges of IPF therapeutic development for successful advancement of therapeutic candidates to in-human studies and beyond. \nJoin experts from the likes of Boehringer Ingelheim\, Genentech\, Pfizer\, AstraZeneca\, BMS\, Pliant\, Galecto\, Vicore\, Avalyn\, Pieris\, Moderna\, Takeda and more who have already saved their places at the meeting. \nSee pricing and registration options here!
URL:https://www.pharmajournalist.com/event/7th-ipf-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230926
DTEND;VALUE=DATE:20230929
DTSTAMP:20260516T004834
CREATED:20230704T142733Z
LAST-MODIFIED:20230704T142733Z
UID:37413-1695686400-1695945599@www.pharmajournalist.com
SUMMARY:2nd mRNA Process Development & Manufacturing Summit
DESCRIPTION:Returning to Boston as the world’s only industry-leading meeting focused on mRNA process development and manufacturing\, join 200+ VPs\, Directors and Heads of Process Development\, MSAT\, Technical Operations\, CMC and more from large pharma\, innovative biotechs\, and academia. \nDownload the program here: https://ter.li/5o4hdl \nThis must-attend meeting will provide you with technical insight and know-how from the largest process development and manufacturing speaker faculty to date\, enabling you to revolutionize your processes for effective industrialization. \nSpanning three tracks dedicated to Research Scale\, IND-Enabling & Clinical Scale\, and Commercial Scale\, this year’s meeting will dive deep into the challenges\, requirements\, innovations and opportunities to improve your design\, development and scale-up solutions from drug substance to drug product for regulatory and market readiness. \nRegister here: https://ter.li/nu15iq
URL:https://www.pharmajournalist.com/event/2nd-mrna-process-development-manufacturing-summit/
LOCATION:Boston Convention and Exhibition Center (BCEC)\, 415 Summer Street\, Boston\, MA\, MA 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231002
DTEND;VALUE=DATE:20231005
DTSTAMP:20260516T004834
CREATED:20230608T110740Z
LAST-MODIFIED:20230608T110740Z
UID:37302-1696204800-1696463999@www.pharmajournalist.com
SUMMARY:5th TIL Therapies Summit
DESCRIPTION:With the first commercial TIL therapy brewing at Iovance\, along with various clinical readouts which are set to come to fruition in 2023\, the race is on for the next generation of modified TIL to enter the clinic. \n \nReturning as the only forum to address bottlenecks in end-to-end TIL development\, the 5th TIL Therapies Summit is designed exclusively for TIL experts to fast-track your program into the clinic and beyond. \nUnite with this niche community across industry and academia as pioneers from Iovance Biotherapeutics\, Turnstone Biologics\, Achilles Therapeutics and Lyell Immunopharma share clinical updates\, next-gen engineering\, and novel innovations to turbocharge preclinical and clinical development of safe\, scalable and effective TIL therapies. \nWith 23+ expert speakers\, 8 new companies and a brand-new Manufacturing & Characterization Bootcamp\, you won’t want to miss this unrivalled opportunity to connect and collaborate with industry leaders. \nDon’t let your team get left behind! Join us as we accelerate the next wave of TIL therapies into the clinic and beyond. Find out more – https://ter.li/mk23q3.
URL:https://www.pharmajournalist.com/event/5th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231009
DTEND;VALUE=DATE:20231011
DTSTAMP:20260516T004834
CREATED:20230810T115308Z
LAST-MODIFIED:20230810T115430Z
UID:37608-1696809600-1696982399@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference & Expo
DESCRIPTION:Wearable Injectors and Connected Devices Conference & Expo \n9 – 10 October 2023 | London\, UK \nhttp://www.wearable-injectors.co.uk/PharmaJournalist-EL \nStrategies to advance digital health and on-body drug devices for large volume delivery \nSAE Media Group are proud to announce the 4th annual Wearable Injectors and Connected Devices conference. As the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. \nThe conference will delve into on-body device design and development\, enhancing digital connectivity for injectable devices\, strategic approaches to wearable device design\, regulatory considerations and primary container considerations for large volume delivery systems. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in October 2023! \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference-expo/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231010
DTEND;VALUE=DATE:20231013
DTSTAMP:20260516T004834
CREATED:20230628T105645Z
LAST-MODIFIED:20230628T105645Z
UID:37366-1696896000-1697155199@www.pharmajournalist.com
SUMMARY:6th Neuropsychiatric Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for Spearheading Non-Psychedelic & Psychedelic R&D \n2023 is booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum\, with notable approvals on the horizon\, as unmet needs in PTSD\, bipolar\, anxiety\, schizophrenia\, depression\, and ADHD become greater and greater. There is\, therefore\, a huge deal of novel and promising research to be discussed this October at the 6th Neuropsychiatric Drug Development Summit. \nWith discovery\, preclinical\, translational\, and clinical scientists from the likes of Biogen\, Otsuka\, AbbVie\, Genentech\, Lundbeck\, Delix Therapeutics\, Atai\, Gilgamesh\, and Cerevel Therapeutics\, don’t miss the field’s favorite conference\, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic. \nTo know more visit: https://ter.li/sar413
URL:https://www.pharmajournalist.com/event/6th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231020
DTSTAMP:20260516T004834
CREATED:20230524T141827Z
LAST-MODIFIED:20230524T141827Z
UID:37236-1697414400-1697759999@www.pharmajournalist.com
SUMMARY:14th World ADC San Diego 2023
DESCRIPTION:The ADC renaissance shows no sign of slowing down with the ground-breaking approval of ELAHERE for platinum resistant ovarian cancer\, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion\, and BMS’ $1 billion+ pact with Tubulis. There has been no better time to reunite the World ADC community and invest in progressing ADCs to front line treatments for patients. \nThe highly anticipated 14th World ADC San Diego (October 16-19\, 2023 | San Diego\, CA) returns as the world’s largest industry-dedicated discussion and networking forum addressing and overcoming the challenges in end-to-end ADC development. \nGain exclusive access to the full event guide to view the full agenda with 120+ industry-leading speakers. \nWhether you’re new to the field or an ADC guru\, there is something for everyone included in this year’s agenda. Some of your must-attend talks per track include: \n\nDiscovery Chemistry: Join Christopher Marvin\, Principal Research Scientist\, AbbVie as he reviews the design and optimization of glucocorticoid receptor modulator payloads for Immunology ADCs\nCellular Biology: Discuss with Robert Lawrence\, Principal Scientist\, Seagen the influence of artificial intelligence on ADC target discovery\nTranslational: Review a best-in-class translational study with Meijuan Li\, Vice President\, Head of Translational Sciences & Biostatistics\, Eisai Oncology\nClinical Lessons: Be the first to hear industry-changing clinical results from ImmunoGen\, Byondis\, Iksuda Therapeutics\, Seagen\, Bliss Bio\, Genentech and Elucidia Oncology\nProcess and Analytical Development: Debate the key considerations for ADC comparability studies in a dedicated roundtable lead by ADC CMC expert\, Julie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nManufacturing and Supply Chain: Explore the manufacturing of novel dolaLock ADCs with supply chain architecture with Engin Ayturk\, Executive Director\, CMC Process Development\, Mersana Therapeutics\n\nAccess to the complete agenda here including a 7-tracked seminar day and 10 industry-beating workshops. \nDon’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had\, and building momentum for the future of this innovative field.
URL:https://www.pharmajournalist.com/event/14th-world-adc-san-diego-2023/
LOCATION:Sheraton San Diego Hotel and Marina\, 1380 Harbor Island Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260516T004834
CREATED:20230718T090856Z
LAST-MODIFIED:20230718T090856Z
UID:37484-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:2nd Operationalise: Early Access Programmes Europe Summit
DESCRIPTION:The Early Access Programmes Summit Europe returns for a second year this October\, aiming to help the industry navigate the notoriously complex European regulatory landscape\, and conquer operational hurdles to provide patients in Europe with early access to medicines. \n \nThis meeting provides a forum to address burning questions and share ideas on topics such as European regulatory guidelines\, labelling\, supply\, and best practices around reimbursement\, integrating of pre- and post-trial access programmes and scoping. \nProviding practical\, valuable case studies is this year’s expert speaker lineup including the likes of GlaxoSmithKline\, Roche\, Novartis\, Sanofi\, and many others! Visit our website to download a free copy of the full event guide to explore the jam-packed 3-day agenda and full speaker faculty. \nWhether you’re a veteran at managing early access programmes and are looking to expand your geo\, or a new entrant to the field\, you’ll leave this conference with the practical lessons and essential connections needed to supercharge your European early access programme across 2023 and beyond. \nTo know more visit: https://bit.ly/3K4BpqO
URL:https://www.pharmajournalist.com/event/2nd-operationalise-early-access-programmes-europe-summit/
LOCATION:Hilton Canary Wharf\, South Quay\, Marsh Wall\, London\, E14 9SH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260516T004834
CREATED:20230831T083951Z
LAST-MODIFIED:20230905T090233Z
UID:37702-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:4th Commercializing Flow Chemistry Summit
DESCRIPTION:Scaling Flow Chemistry for Sustainability\, Safety and Speed to Market  \nWith the growing demand for better flow technology\, the 4th Commercializing Flow Chemistry Summit is your must-attend meeting to deep-dive into transforming your process efficiency\, emerging technology toolbox and economic gains through strategic flow chemistry. \nWith unmissable case studies from the likes of Novartis\, Boehringer Ingelheim\, Sanofi\, AbbVie\, Eli Lilly and Takeda\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nElevate Sustainability with Industry Leaders: Join forces with Merck\, Eli Lilly and AbbVie to integrate sustainable practices seamlessly into your workflow\, enhancing both environmental responsibility and operational excellence\nUnlock Efficiency through Automation: Discover the power of automation in flow chemistry\, following the footsteps of efficiency leaders like Sanofi\, Takeda\, and Boehringer Ingelheim\, and optimize your processes for peak performance\nMaster Multi-Step Techniques: Gain expert insights from Boehringer Ingelheim on handling multi-step reactions in both flow and batch setups\, fine-tuning your manufacturing processes for maximum efficiency and output\n\nDon’t miss this opportunity to streamline your continuous chemistry research into scaled commercial applications\, and together with 80+ process chemists\, engineers\, and modellers\, go beyond reaction to work up optimization to develop winning processes quicker and expedite your drug development. \nTo know more visit: https://ter.li/jfxs1m
URL:https://www.pharmajournalist.com/event/4th-commercializing-flow-chemistry-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231017
DTEND;VALUE=DATE:20231020
DTSTAMP:20260516T004834
CREATED:20230724T153358Z
LAST-MODIFIED:20230724T153358Z
UID:37509-1697500800-1697759999@www.pharmajournalist.com
SUMMARY:2nd Innate Killer Summit Europe 2023
DESCRIPTION:The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T\, NK\, iNKT\, neutrophil\, and macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through effective and scalable engineering\, engager and combination strategies that promote safe\, potent and persistent innate immune therapies following application. \nDon’t miss this chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Lift Biosciences\, Mink Therapeutics\, Affimed\, Carisma Therapeutics\, Arovella Therapeutics and receive 3-days of some of the best scientific and data driven case studies that will help propel your innate immune therapy into the clinic and beyond. Learn more – https://ter.li/nkcwg3
URL:https://www.pharmajournalist.com/event/2nd-innate-killer-summit-europe-2023/
LOCATION:Crowne Plaza London\, Royal Victoria Dock\, Western Gateway\, London\, E16 1AL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231026
DTSTAMP:20260516T004834
CREATED:20230628T104642Z
LAST-MODIFIED:20230628T104642Z
UID:37361-1698019200-1698278399@www.pharmajournalist.com
SUMMARY:11th IMPACCT: Real World Evidence Summit 2023
DESCRIPTION:Returning for its 11th year\, the IMPACCT: Real World Evidence Summit 2023 will deep dive into the use of RWE for regulatory submissions and clinical trial innovation to unlock unstructured healthcare data and transform disease treatment. \nJoin 100+ senior leaders in RWE\, RWD\, real world analytics & epidemiologists from pharma and biotech to take part in this three-day summit with over 18 hours of exclusive content. \nDon’t miss your unique opportunity to explore how to leverage RWE to target patient populations and drive DE&I into trials. For more information go to: https://ter.li/db1xte
URL:https://www.pharmajournalist.com/event/11th-impacct-real-world-evidence-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231025
DTSTAMP:20260516T004834
CREATED:20230810T114239Z
LAST-MODIFIED:20230810T114239Z
UID:37598-1698019200-1698191999@www.pharmajournalist.com
SUMMARY:Biosensors for Medical Wearables Conference and Expo
DESCRIPTION:Biosensors for Medical Wearables Conference and Expo  \n*In collaboration with Medical Design Briefs* \nOctober 23-24\, 2023 | Boston\, MA\, USA \nhttp://www.biosensors-medical-wear.com/PharmaJournalist-WL \nSAE Media Group’s 3rd Annual Biosensors for Medical Wearables Conference will be back for 2023 in Boston to bring together device developers\, MedTech\, component manufacturers and big pharma to share and discuss the exciting advances in the medical wearable technology landscape. \nThe wearable biosensors market has grown significantly in recent years leading to increasingly growing potential for medical applications and at home alternatives for patients. With growing applications and potential in remote patient monitoring\, diagnosis\, therapeutics and detection of disease\, wearable sensors are attracting considerable interest due to their opportunities in better supporting patients\, clinical outcomes and decisions. Furthermore\, AI and connected technologies are furthering the potential opportunities of this industry. However\, challenges including flexibility of wearable devices\, the collection of clinical-grade data and advanced battery technologies still remain for the industry to overcome. This year’s conference looks to address these hot topics through case studies and industry insights. \nThis is a must attend event\, giving you the chance to engage in the latest innovations that are accelerating the wearable biosensors industry. We hope to welcome you in October 2023! \nReasons to attend: \n\nBenchmark against and explore the latest biosensor technologies for wearable medical devices from Abbott\, Empatica and Hexoskin\nDelve into the potential of wearable sensors and digital tools in decentralized diagnosis including a Johnson & Johnson case study on the Heartline project\nLearn how game changing companies such as Philips and Medtronic are utilizing wearables to maximize remote patient monitoring opportunities for wider patient populations\nExplore how AI and machine learning technologies are enabling optimized data collection and streamlined data analysis\nDiscover cutting-edge biosensor therapeutic applications for neurology with Neurasantys and a panel discussion on future medical opportunities\n\nWho you can meet? \n\nAndreas Caduff\, Strategic Advisory Board\, DiME\nLorelie Villarete\, Manager\, Clinical Affairs\, Lingo Sensing Technology Unlimited Company (an Abbott Company)\nTim Callahan\, VP Scientific Affairs\, Philips\nKara Chappie\, Director and Project Lead\, Pfizer\nJason Case\, Vice President\, Research and Development\, Patient Monitoring\, Medtronic\nJames Mault\, MD\, Founder and CEO\, BioIntellisense\, Inc.\nJasmin Imsirovic\, Associate Director\, Takeda\nJanet Nikolovski\, New Venture Lead – Genitourinary Oncology\, Johnson & Johnson
URL:https://www.pharmajournalist.com/event/biosensors-for-medical-wearables-conference-and-expo/
LOCATION:COURTYARD BY MARRIOTT BOSTON DOWNTOWN\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231030
DTEND;VALUE=DATE:20231102
DTSTAMP:20260516T004835
CREATED:20230803T103923Z
LAST-MODIFIED:20230803T103923Z
UID:37564-1698624000-1698883199@www.pharmajournalist.com
SUMMARY:CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:CRISPR-based therapies are undergoing a remarkable evolution\, with drug developers striving to enhance the safety\, precision and efficacy of their products. As this paradigm takes place\, more complex CRISPR structures necessitate cutting-edge advancements in analytical methods and tools to effectively characterize the genome-edited products utilizing CRISPR technology. \nAs industry experts tread unchartered territory\, the inaugural CRISPR-Based Therapy Analytical Development Summit has been convened\, gathering more than 60 distinguished experts in analytical development devoted to the creation\, refinements and implementation of more robust analytical tools specifically tailored to CRISPR-based constructs. \nWithin this intimate space\, we will adopt a shared consensus and delve into a comprehensive array of analytical techniques central to any CRISPR-based toolkit. Topics of discussion will span pioneering technology that includes everything from novel methods to characterize the guide RNA and whole CRISPR complex\, to the use of next-generation sequencing (NGS) to detect and assess off-targets for superior safety evaluations. \nIn response to the regulatory bodies’ insistence on high-quality data to substantiate the safety and efficacy of genome-edited products\, this summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products. \nIf your role centers around analytical expertise and gene edited specialization\, this meeting will enable you to streamline your analytical development process and connect in a shared goal to deliver safer therapies\, with superior therapeutic benefit to patients faster. \nTo know more visit: https://ter.li/28jg6x
URL:https://www.pharmajournalist.com/event/crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231106
DTEND;VALUE=DATE:20231110
DTSTAMP:20260516T004835
CREATED:20230628T105940Z
LAST-MODIFIED:20230628T105940Z
UID:37371-1699228800-1699574399@www.pharmajournalist.com
SUMMARY:5th Gene Therapy for Neurological Disorders Summit
DESCRIPTION:Accelerating More Transformative Gene Therapies for CNS Disorders \nDespite a challenging 2022 for Gene Therapy developers targeting the CNS\, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community. \nThe 5th Gene Therapy for Neurological Disorders Summit is your comprehensive 4-day event to stay ahead of cutting-edge developments\, overcome delivery challenges\, address translational bottlenecks\, and create a bulletproof clinical development strategy\, to propel the next wave of CNS gene therapies forward. \nThis summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights. \nNow that the neurological gene therapy field has been given a renewed sense of direction\, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders. \nTo know more visit: https://ter.li/iblyl1
URL:https://www.pharmajournalist.com/event/5th-gene-therapy-for-neurological-disorders-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231106
DTEND;VALUE=DATE:20231108
DTSTAMP:20260516T004835
CREATED:20230912T141209Z
LAST-MODIFIED:20230912T141209Z
UID:37773-1699228800-1699401599@www.pharmajournalist.com
SUMMARY:Extractables & Leachables Europe 2023
DESCRIPTION:Join us at this year’s much-anticipated Extractables and Leachables Europe\, taking place on 6-7 November 2023 in Amsterdam. \nThis year’s conference promises to once again provide you with everything you need to know about this ever-evolving sector. Extractables and leachables examination is continuously growing in importance. Given the current scrutiny paid by governing bodies including the FDA and MHRA\, understanding the best practice and guidelines to carry out extractables and leachables studies is imperative in order to eliminate risk and potential development delays. \nWhatever your level or position\, and whether you’re from a CRO\, pharmaceutical manufacturer\, packaging specialist\, instrument or equipment manufacturer\, research or academic institution\, chemical company or OEM – this conference has something for everyone. \nWith speakers from reputable companies like Element\, GSK Vaccines\, Aptar Pharma\, Octapharma\, Sartorius Stedim Biotech and numerous others\, the agenda is bursting with insights\, helping the conference be the most exceptional one to date. \nDescribed by a previous attendee as ‘the place to be for the E&L community’\, this is a mist-attend event for anyone working in the industry. \nFind out more here: https://www.eandl-conference.com/extractables-and-leachables-europe \nIn addition to organising the renowned E&L events in Europe\, US and China\, Smithers also have a long history in providing E&L and medical device testing across the globe. Find out more at www.smithers.com.
URL:https://www.pharmajournalist.com/event/extractables-leachables-europe-2023/
LOCATION:Steinberger Airport Hotel\, Stationsplein Zuid-West 951\, 1117 CE Schiphol\, Netherlands\, 1117 CE\, Netherlands
ORGANIZER;CN="Smithers":MAILTO:pregnault@smithers.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231107
DTEND;VALUE=DATE:20231108
DTSTAMP:20260516T004835
CREATED:20230829T092031Z
LAST-MODIFIED:20230829T092031Z
UID:37692-1699315200-1699401599@www.pharmajournalist.com
SUMMARY:PURIFY’23
DESCRIPTION:PURIFY – Chromatography Purification Conclave \nPURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nTo know more visit: https://www.purifyconclaves.com/
URL:https://www.pharmajournalist.com/event/purify23/
LOCATION:ITC KOHENUR\, HYDERABAD\, INDIA
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231107
DTEND;VALUE=DATE:20231110
DTSTAMP:20260516T004835
CREATED:20231002T095350Z
LAST-MODIFIED:20231002T095350Z
UID:37885-1699315200-1699574399@www.pharmajournalist.com
SUMMARY:7th Microbiome Movement – Human Nutrition Summit
DESCRIPTION:The 7th Microbiome Movement – Human Nutrition Summit will unite 100+ human nutrition leaders this November in Livingston\, NJ to optimize product development and consumer acceptance of microbiome-based food and nutritional products. Join the only industry led meeting dedicated to moving the needle on scientifically validated\, microbiome modulating\, nutritional product development. \nFrom developing pre-\, pro-\, or post-biotics\, functional food\, microbiome modulating ingredients\, to other interventions that provide microbial-mediated health benefits\, this meeting offers unrivalled opportunities for those working in the microbiome human nutrition space. \nJoin us in Livingston\, NJ\, this November to hear invaluable insights from the likes of Bifidice\, Danone\, Holobiome\, ADM\, Immune Biome\, and more! \nView the full event guide here: https://ter.li/2ppxtz \nOffering earlybird rates\, exclusive group discounts and a brand-new\, post-conference consumer focus day\, now is the time to register. Don’t miss out\, secure your place now: https://ter.li/8algsb
URL:https://www.pharmajournalist.com/event/7th-microbiome-movement-human-nutrition-summit/
LOCATION:Westminster Hotel\, 550 W Mt Pleasant Ave\, Livingston\, NJ\, 07039\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231127
DTEND;VALUE=DATE:20231201
DTSTAMP:20260516T004835
CREATED:20230803T103428Z
LAST-MODIFIED:20230803T103428Z
UID:37560-1701043200-1701388799@www.pharmajournalist.com
SUMMARY:5th Annual Gene Therapy Analytical Development Summit 2023
DESCRIPTION:Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy\, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely\, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic. \nIn this context\, the 5th Annual Gene Therapy Analytical Development is returning in 2023\, uniting 400+ analytical experts to explore how the latest analytical methods are being developed and applied to guarantee the quality\, consistency\, safety\, and efficacy of gene therapy products. \nJoin biopharma colleagues specializing in bioassays\, molecular biology\, physicochemical properties\, quality\, process development and regulation across 4 days of niche\, expert presentations\, and dedicated networking opportunities. This is your must-attend meeting to collaborate ideas\, success and challenges to capitalize on the technological advances in analytical development to reach the ultimate goal of bringing safer\, efficacious therapies to patients more quickly and effectively. \nTo know more visit: https://ter.li/qf50s3
URL:https://www.pharmajournalist.com/event/5th-annual-gene-therapy-analytical-development-summit-2023/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231127
DTEND;VALUE=DATE:20231130
DTSTAMP:20260516T004835
CREATED:20230925T125234Z
LAST-MODIFIED:20230925T125234Z
UID:37847-1701043200-1701302399@www.pharmajournalist.com
SUMMARY:7th Obesity & NASH Drug Development Summit
DESCRIPTION:Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss\, a new record for the obesity field has been set and the time to get ahead of the curve is now. In parallel\, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist\, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers. \nReuniting metabolic experts to enable the assessment of the competitive landscape\, the 7th Obesity & NASH Drug Development Summit is uniquely positioned to capture all the latest breakthroughs and research you need to join the race and commercialize your GLP-1 RAs\, tri-agonists\, dual agonists\, tetra-specific drugs\, glucocorticoid receptor modulators and more. \n2023 is an exciting year due to the evolution in digital pathology\, artificial intelligence\, omics\, multifunctional molecules\, non-invasive biomarkers\, target discovery and liver models\, this is your timely meeting dedicated to bringing the metabolic community closer to navigate the route to even more approvals. However\, as industry gets closer to successes\, challenges remain. \nKeen to overcome these discovery\, regulatory\, clinical\, and commercial hurdles? \nJoin 160+ experts at the largest gathering of obesity and NASH industry drug developers from Eli Lilly\, Novo Nordisk\, Madrigal\, Akero\, Gilead\, Pfizer\, AstraZeneca\, Gilead\, Inventiva and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH. Don’t miss your opportunity to hear from 42+ metabolic experts over 3 jam-packed days with all the latest end-to-end updates to advance your drug development. \nTo know more visit: https://bit.ly/465Aa3m
URL:https://www.pharmajournalist.com/event/7th-obesity-nash-drug-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260516T004835
CREATED:20230724T153728Z
LAST-MODIFIED:20230724T153728Z
UID:37515-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:Enter the inaugural Cell Therapy for Autoimmune Disease Summit\, a pioneering platform singularly focused on uniting and empowering this community for the first time. Experts will delve into cutting-edge frontiers of pre-clinical\, translational\, and clinical advancements encompassing all cell-based therapies\, including CAR-T\, Treg\, and MSC\, with the shared objective of developing better therapies for patients with chronic autoimmune diseases. \nDon’t miss out on your opportunity to network with 80+ key opinion leaders including Cabaletta Bio\, Kyverna Therapeutics\, AstraZeneca\, Quell Therapeutics\, Novartis\, and more. Learn more – https://ter.li/6xwjrk
URL:https://www.pharmajournalist.com/event/cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sonesta Philadelphia Rittenhouse Square\, 1800 Market Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260516T004835
CREATED:20230822T114102Z
LAST-MODIFIED:20230822T114159Z
UID:37658-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Donor Selection & Cell Source Summit 2023
DESCRIPTION:The Donor Selection & Cell Source Summit is your ultimate platform to explore the latest global regulatory requirements and differences on donor testing\, understand the novel genome sequencing data being used to inform donor selection\, and forge new partnerships to ease logistical coordination with donation sites to ensure exclusive availability of selected donor pools. \nJoin Senti Biosciences\, Poseida Therapeutics\, Caribou Bio\, Allogene and more to advance your knowledge on donor selection\, management and sustainability to ensure a consistent and reliable supply of cell source material required for clinical trials and beyond. \nDownload a copy of the event guide to view the 3-day jam-packed agenda\, expert speaker faculty and exclusive pre-conference workshop day: https://ter.li/t81hko
URL:https://www.pharmajournalist.com/event/donor-selection-cell-source-summit-2023/
LOCATION:The Clift Royal Sonesta\, 495 Geary Street\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260516T004835
CREATED:20230825T133450Z
LAST-MODIFIED:20230825T133450Z
UID:37674-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:4th Annual CRISPR 2.0 Congress 2023
DESCRIPTION:CRISPR represents the next frontier in the cell and gene therapy landscape. Spearheaded by the first gene edited therapeutic awaiting FDA approval\, a mounting wave of innovative technology developments and therapeutic applications are leading to a paradigm shift in our global healthcare systems. \nTo this end\, the 4th Annual CRISPR 2.0 Congress is your definitive guide to showcasing the latest and greatest CRISPR tools being developed and applied in the therapeutic setting. \nTo know more visit: https://ter.li/rqwuyn
URL:https://www.pharmajournalist.com/event/4th-annual-crispr-2-0-congress-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260516T004835
CREATED:20230829T091427Z
LAST-MODIFIED:20230829T091427Z
UID:37688-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Advanced Purification for Complex Biologics Summit
DESCRIPTION:The Advanced Purification for Complex Biologics Summit is the first and only standalone conference focused on purification for biologics and novel modalities bringing together purification\, CMC and MSAT professionals to collaborate and remove purification bottlenecks to meet market delivery timelines. \nThis in-depth 3-day event will feature the latest breakthroughs and cutting-edge content in AI and digital learning tools to help you save time during downstream processing and boost efficiency. \nThis is your unique opportunity to meet 60+ purification and downstream processing experts including Sanofi\, Takeda\, Eli Lilly\, AstraZeneca and Regeneron as they talk you through machine learning\, predictive modelling\, and consumables advancements to empower your process optimization\, moving a step closer to 100% product purity. \nTo know more visit: https://ter.li/80pxjz
URL:https://www.pharmajournalist.com/event/advanced-purification-for-complex-biologics-summit/
LOCATION:Sonesta Philadelphia Rittenhouse Square\, 1800 Market Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260516T004835
CREATED:20230915T100043Z
LAST-MODIFIED:20230915T100043Z
UID:37804-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd ADC Target Selection Summit
DESCRIPTION:The 3rd ADC Target Selection Summit (December 5-7 | Boston\, MA). This is the ultimate cover-to-cover conference providing insights to help you optimize the pairing of target\, antibody\, and linker-payload and develop the next generation of clinically successful ADCs beyond HER2 and TROP2. \nSee the full program here. \nAs the number of new clinical ADC targets continues to increase\, this year’s meeting will have a greater focus on identifying and validating novel targets\, re-examining what makes a good target\, and delving into the use of proteomics to ensure you get the first step of drug development right. \nHere are some of the agenda highlights you cannot afford to miss: \n\nJoin Cancer Research Horizons to learn “Overcoming Hurdles in Validating Novel Targets for Clinically Applicable ADCs” and hear how an unbiased proteomics approach with patient samples was used to discover a clinically relevant ADC target for multiple myeloma\nHear from Ziel Bio on “Discovering Cell Surface Plectin: A Highly Promising Target for Multiple Solid Tumors” to understand how the hypothesized function of plectin highlights it as a good ADC target\, and learn how ZB131 can selectively bind to CSP improving internalization and minimizing off-target effects\nGain insights from AstraZeneca on “A Case Study on Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic” highlighting the target selection process and reasons behind the choice of pursuing HER2\, target and antibody considerations; and emphasizing challenges and successes in the use of this target for ADCs to help you prepare for your development.\n\nTake a look at the full speaker faculty and session details. \nUniting 100+ of your peers working in biology\, discovery and oncology research\, this unique forum will provide you with an exclusive opportunity to learn and network with other ADC developers who are living and breathing targets all in one room.
URL:https://www.pharmajournalist.com/event/3rd-adc-target-selection-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260516T004835
CREATED:20230920T102331Z
LAST-MODIFIED:20230920T102331Z
UID:37817-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd Applied Biocatalysis Summit
DESCRIPTION:Enzyme Engineering Enabling Scalable Industrial Biotransformation for Sustainable API Production \nIn 2023\, an era of advanced enzyme engineering technology is rapidly enabling the generation of game-changing enzymes for novel transformations. As witnessed for Merck’s Islatravir and BMS’ ERED/KRED biocatalytic cascade recognition\, industries are fast transitioning towards biocatalysis to capitalize on more sustainable means of synthesis. The 3rd Applied Biocatalysis Summit is your must-attend meeting dedicated to accelerating enzyme discovery and reaction route development\, through to scaling process chemistry for industrial applications. \nWith unmissable case studies from the likes of Merck\, Amgen\, Sanofi\, Biogen\, GSK\, and Pfizer\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nGaining valuable insights on chemoenzymatic catalysis research\, combining heterogeneous and homogeneous catalysis and making valued functionality using biocatalysis\, in water with Bruce Lipshutz\, Professor of Chemistry\, University of California\, Santa Barbara\nLearn how new technologies are adding efficiencies to biocatalysis’ adoption\, including AI/ML approaches\, improved screening for reaction prediction & new chemistry discoveries with Merck & Pfizer\nEngage in dynamic panel discussions addressing how cross-departmental collaboration enable the faster assessment and introduction of enzymatic catalysed reactions as early as possible with AbbVie\, Biogen & Neorocrine Biosciences\n\nDon’t miss this opportunity to join trailblazers and accelerate enzyme discovery and engineering\, discover carbon footprint-reducing reactions and refine your process scaling strategies.
URL:https://www.pharmajournalist.com/event/3rd-applied-biocatalysis-summit/
LOCATION:The Study at University City\, 20 S 33rd Street\, Philadelphia\, PA\, 19104\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR